Eli M. Wallace Receives Stock Award at BridgeBio Oncology Therapeutics Inc (BBOT) — SEC Form 4, Oct 06, 2025
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Eli M. Wallace CIK 0001776352 |
Director
CEO
|
Eli M. Wallace at BridgeBio Oncology Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at BridgeBio Oncology Therapeutics Inc
| 2026-01-06 | Award | — | View |
| 2025-12-12 | - | — | View |
| 2025-08-28 | Award | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.44 | 2025-10-02 | A - Award/Grant | 1,614,400 A | $0.00 | 2035-10-01 | 1,614,400 Common Stock | Direct |
Footnotes (1)
- F1
- 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Show more
Related filings at BridgeBio Oncology Therapeutics Inc
5%+ Holders · 13D/G
7 filers
-
Chen Bihua 22.3%
-
Deerfield Mgmt, L.P. 6.2%
-
BridgeBio Pharma LLC 17.5%
-
Helix Holdings II LLC 22.6%
Other insiders at BridgeBio Oncology Therapeutics Inc
GET /v1/forms/4/0001193125-25-231917
API docs
View Original SEC Filing